Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-Fresenius vs Thymoglobulin for GVHD Prevention in Haplo-HSCT
NCT03631563Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Mar 2013
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of antithymocyte globulin rabbit in graft-versus-host disease (GVHD) (2 arms), sponsored by Fujian Medical University. Primary endpoint: Incidence of Graft-versus-host Disease at 1 year. Status: unknown.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03631563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631563.